“Lazarus response” of nivolumab in a frail patient with non‐small‐cell lung cancer

Lung cancer has aggressive behaviour which often progresses rapidly with disseminated disease and leads to poor performance status (PS) in patients. Because cytotoxic chemotherapy is not recommended under these conditions, there are currently no alternative therapeutic options other than providing s...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Takayuki, Takeuchi, Mayumi, Nishimi, Yurika, Saitoh, Masahiko, Takeda, Sorou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322219/
https://www.ncbi.nlm.nih.gov/pubmed/30631445
http://dx.doi.org/10.1002/rcr2.247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322219/
https://www.ncbi.nlm.nih.gov/pubmed/30631445
http://dx.doi.org/10.1002/rcr2.247

Ejemplares similares